Leading independent proxy advisory firms iss and glass lewis recommend acer therapeutics shareholders vote "for" the proposed merger and related proposals

Newton, mass., nov. 02, 2023 (globe newswire) -- acer therapeutics inc. (nasdaq: acer ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that institutional shareholder services inc. (iss) and glass, lewis & co. llc (glass lewis) recommended that acer shareholders vote "for" the proposed merger with zevra therapeutics, inc. and the related proposals in the company's proxy statement and prospectus for the special meeting of its shareholders to be held on november 8, 2023 at 11:00 a.m.
ACER Ratings Summary
ACER Quant Ranking